FibroBiologics, Inc.
FBLG
$0.35
$0.025.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.25M | 2.45M | 2.75M | 2.36M | 2.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.04M | 4.49M | 4.53M | 3.71M | 3.35M |
| Operating Income | -5.04M | -4.49M | -4.53M | -3.71M | -3.35M |
| Income Before Tax | -5.78M | -4.66M | -4.97M | -3.10M | -500.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.78M | -4.66M | -4.97M | -3.10M | -500.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.78M | -4.66M | -4.97M | -3.10M | -500.00K |
| EBIT | -5.04M | -4.49M | -4.53M | -3.71M | -3.35M |
| EBITDA | -4.97M | -4.43M | -4.48M | -3.67M | -3.31M |
| EPS Basic | -0.13 | -0.12 | -0.14 | -0.09 | -0.01 |
| Normalized Basic EPS | -0.08 | -0.08 | -0.08 | -0.06 | -0.01 |
| EPS Diluted | -0.13 | -0.12 | -0.14 | -0.09 | -0.01 |
| Normalized Diluted EPS | -0.08 | -0.08 | -0.08 | -0.06 | -0.01 |
| Average Basic Shares Outstanding | 43.07M | 38.64M | 36.67M | 34.13M | 33.52M |
| Average Diluted Shares Outstanding | 43.07M | 38.64M | 36.67M | 34.13M | 33.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |